MIM
SABS icon

MetLife Investment Management’s SAB Biotherapeutics SABS Stock Holding History

MetLife Investment Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
+28,015
New +$104K ﹤0.01% 2742

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MetLife Investment Management's SABS Position: Q2 2026 in Review

MetLife Investment Management opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 28,015 shares worth $109K. The stake represents ﹤0.01% of the portfolio and ranks #2742 among its holdings.

87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • MetLife Investment Management held 28,015 shares of SAB Biotherapeutics worth $109K as of Q2 2026.
  • SAB Biotherapeutics was a new MetLife Investment Management position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2742 holding.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.